HSCS News & Events

HeartSciences announced that it has signed a commercial agreement with St. Vincent Health to deploy the MyoVista Insights platform.

HeartSciences announced that the University of the West of England, UWE, has adopted the Company's MyoVista Insights platform and MyoVista wavECG device as its exclusive ECG technologies to establish a Reference Center for ECG Education and Technology. Under the agreement, MyoVista Insights and the MyoVista wavECG device will be used exclusively across UWE's cardiac and physiological science teaching programs to train the next generation of cardiac scientists.

HeartSciences announced that Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for independent hospitals within its high-value networks. This collaboration will provide Cibolo Health's network of 123 independent hospitals across six states with access to a modern, cloud-native ECG management platform. "We are delighted to partner with Cibolo Health, which is focused on ensuring its member hospitals and clinics have access to best-in-class solutions that support high-quality, cost-effective care," said Andrew Simpson, CEO of HeartSciences. "This collaboration represents an important step in expanding access to our MyoVista Insights platform across a broad network of independent hospitals."

HeartSciences submitted its MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG functionality while serving as a platform capable of hosting AI-ECG algorithm. Following the recent publication of updated American Society of Echocardiography guidelines for the assessment of Left Ventricular Diastolic Dysfunction, including revised age-based thresholds for cardiac relaxation, the Company elected to separate the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG software algorithm. This approach allows the Company to complete additional development and validation work required to update the AI-ECG algorithm to align with the new clinical standards, while advancing the regulatory review of the device independently. Separating the submissions is intended to simplify the regulatory pathway and accelerate clearance of the device. The strategy also preserves flexibility for future deployment of the AI-ECG algorithm across both the MyoVista wavECG device and the Company's MyoVista Insights HIT software platform